Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol and cardiovascular events in the FOURIER trial. In this prespecified analysis of FOURIER, we investigated the efficacy and safety of evolocumab by diabetes status and the effect of evolocumab on gl...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The lancet. Diabetes & endocrinology Ročník 5; číslo 12; s. 941
Hlavní autoři:	Sabatine, Marc S, Leiter, Lawrence A, Wiviott, Stephen D, Giugliano, Robert P, Deedwania, Prakash, De Ferrari, Gaetano M, Murphy, Sabina A, Kuder, Julia F, Gouni-Berthold, Ioanna, Lewis, Basil S, Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, Pedersen, Terje R
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.12.2017
Témata:	Adult Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Anticholesteremic Agents - adverse effects Anticholesteremic Agents - therapeutic use Blood Glucose - drug effects Blood Glucose - metabolism Cardiovascular Diseases - blood Cardiovascular Diseases - chemically induced Cardiovascular Diseases - prevention & control Diabetes Mellitus - blood Diabetes Mellitus - chemically induced Diabetes Mellitus - drug therapy Double-Blind Method Female Follow-Up Studies Humans Male Middle Aged Proprotein Convertase 9 - antagonists & inhibitors Risk Factors Treatment Outcome
ISSN:	2213-8595, 2213-8595
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!